α-n-butylcyclohexanecarboxylic acid | 62410-48-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: α-n-butylcyclohexanecarboxylic acid
• 英文别名: 1-butyl-cyclohexanecarboxylic acid；1-Butyl-cyclohexancarbonsaeure；1-Butylcyclohexane-1-carboxylic acid
• CAS: 62410-48-4
• 化学式: C₁₁H₂₀O₂
• 分子量: 184.279
• InChiKey: SQQBGYGZHHXUPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  α-n-butylcyclohexanecarboxylic acid 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 14.5h， 生成 N-(1-Butylcyclohexylcarbonyl)valin
  参考文献：
  名称：

  Wegmann, Helmut; Steglich, Wolfgang, Chemische Berichte, 1981, vol. 114, # 7, p. 2580 - 2594

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氢溴酸 、 溶剂黄146 作用下， 生成 α-n-butylcyclohexanecarboxylic acid
  参考文献：
  名称：

  Aminoesters of 1-Substituted Alicyclic Carboxylic Acids

  摘要：

  DOI：

  10.1021/ja01173a044

文献信息

• [EN] CATALYTICS ASYMMETRIC ACTIVATION OF UNACTIVATED C-H BONDS, AND COMPOUNDS RELATED THERETO<br/>[FR] ACTIVATION CATALYTIQUE ASYMETRIQUE DE LIAISONS C-H INACTIVEES ET COMPOSES ASSOCIES
  申请人：UNIV BRANDEIS

  公开号：WO2006026053A1

  公开（公告）日：2006-03-09

  One aspect of the present invention is directed in part to catalytic and stereoselective functionalization of unactivated C-H bonds of simple organic substrates. The compounds and methods provided herein allow one to control the stereochemistry in a C-H activation step, activate substrates containing α-hydrogens next to the directing group, and remove a directing group under mild conditions. One aspect of the present invention relates to a transition-metal-catalyzed method for selective and asymmetric oxidation of carbons located in a β- or Ϝ-position relative to an auxiliary. Another aspect of the invention relates to the enantiomerically-enriched substrates and the enantiomerically-enriched products formed via said method. In certain embodiments, oxazoline and oxazinone directing groups are used. In addition, the Boc protecting group has been identified as a directing group which does not necessitate removal.

  本发明的一个方面部分涉及简单有机底物中未活化C-H键的催化和对映选择性官能团化。本发明提供的化合物和方法允许在C-H活化步骤中控制立体化学，活化含有邻近导向基团的α-氢的底物，并在温和条件下移除导向基团。本发明的另一方面涉及一种过渡金属催化的方法，用于选择性和非对称氧化位于辅助基团β-或Ϝ-位置上的碳。发明的另一个方面涉及通过所述方法形成的对映体富集的底物和对映体富集的产品。在某些实施例中，使用了恶唑啉和恶嗪酮导向基团。此外，Boc保护基团被识别为不需要移除的导向基团。
• [EN] SUBSTITUTED AMINOTHIAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE<br/>[FR] DÉRIVÉS D'AMINOTHIAZOLE SUBSTITUÉS, COMPOSITIONS PHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：TRANSTECH PHARMA INC

  公开号：WO2010025142A1

  公开（公告）日：2010-03-04

  Substituted aminothiazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted aminothiazole, and methods of use in treating human or animal disorders. The compounds may be useful as inhibitors of action of AgRP on a melanocortin receptor and thus may be useful for the management, treatment, control, or the adjunct treatment of diseases which may be responsive to the modulation of melanocortin receptors including obesity-related disorders.

  替代氨基噻唑衍生物，其制备方法，含有替代氨基噻唑的药物组合物，以及在治疗人类或动物疾病中的使用方法。这些化合物可能作为AgRP对黑色素皮质素受体作用的抑制剂而有用，因此可能有助于管理、治疗、控制或辅助治疗对黑色素皮质素受体调节敏感的疾病，包括与肥胖相关的疾病。
• [EN] NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES<br/>[FR] DÉRIVÉS DE THIOPHÈNE NON FUSIONNÉS ET LEURS UTILISATIONS
  申请人：ENYO PHARMA

  公开号：WO2019154953A1

  公开（公告）日：2019-08-15

  The present invention relates to a new class of non-fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.

  本发明涉及一类新型非融合噻吩衍生物及其用于治疗感染、癌症、代谢性疾病、心血管疾病、铁贮存紊乱和炎症性疾病等疾病的用途。
• [EN] BENZIMIDAZOLES AND INDOLES AS TARO INHIBITORS<br/>[FR] BENZIMIDAZOLES ET INDOLES UTILISÉS COMME INHIBITEURS DE TARO
  申请人：MERCK SHARP & DOHME

  公开号：WO2017106134A1

  公开（公告）日：2017-06-22

  Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a β-lactam antibiotic.

  化学结构式I的新型化合物及其药学上可接受的盐，是TarO的抑制剂，可用于预防、治疗和抑制由TarO介导的疾病，如细菌感染，包括革兰氏阴性细菌感染和革兰氏阳性细菌感染，例如耐甲氧西林金黄色葡萄球菌和耐甲氧西林表皮葡萄球菌，单独或与β-内酰胺类抗生素联合使用。
• [EN] MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE<br/>[FR] DERIVES DE L'AZOLE ET DERIVES BICYCLIQUES FUSIONNES DE L'AZOLE, AGENTS THERAPEUTIQUES
  申请人：TRANSTECH PHARMA INC

  公开号：WO2003075921A2

  公开（公告）日：2003-09-18

  This invention provides certain compounds of formula I wherein A1 is O, S or -N(R2)-, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer’s disease, erectile dysfunction, and tumor invasion and metastasis.

  本发明提供了一些公式I的化合物，其中A1是O，S或-N（R2）-，它们的制备方法，包括这些化合物的制药组合物，以及它们在治疗人类或动物疾病方面的用途。本发明的化合物可作为高级糖基化终产物（AGEs），S100 / calgranulin / EN-RAGE，β-淀粉样蛋白和amphoterin等配体与其受体（RAGE）之间相互作用的调节剂，并用于治疗由RAGE引起的人类疾病的管理，治疗，控制或辅助治疗。这些疾病或疾病状态包括急性和慢性炎症，糖尿病晚期并发症的发展，如增加的血管通透性，肾病，动脉粥样硬化和视网膜病变，阿尔茨海默病的发展，勃起功能障碍以及肿瘤侵袭和转移。